Dr Paul T. Menzel joins Ethics Talk to discuss his article: "How Should Willingness-to-Pay Values of Quality-Adjusted Life-Years Be Updated and According to Whom?"
Beatrice L. Brown joins Ethics Talk to discuss her article, coauthored with Dr Aaron S Kesselheim: "How Should Clinicians and Organizations Assess Risks and Benefits of First-in-Human Implantation of Investigational Devices?"
Elizabeth Boskey, PhD, MPH, MSSW, Amir Taghinia, MD, and Oren Ganor, MD
Training should be implemented to respond to clinical staff members’ concerns about trans patients occupying sex-segregated spaces and to help mitigate anti-trans bias.
AMA J Ethics. 2018;20(11):E1067-1074. doi:
10.1001/amajethics.2018.1067.
Therapeutic misconception—a false belief that individuals will benefit from participating in research—can bias informed consent. Ethics consultants can help by engaging participants’ and researchers’ understandings of risks and benefits and by asking good questions about the influences of researchers’ enthusiasm.
AMA J Ethics. 2018;20(11):E1100-1106. doi:
10.1001/amajethics.2018.1100.
Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.